Diabetes remains the leading cause of chronic kidney disease and with its increased prevalence the risk for Diabetic Kidney Disease (DKD) continues to rise and has a significant impact on diabetes morbidity and mortality as well as health care resources. There is a clear need to clinicians and patients for new treatments to limit the burden of DKD. Three classes of non-insulin therapy for type 2 diabetes mellitus (T2DM), dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon-like peptide 1 (GLP1) agonists, and sodium glucose co-transporter 2 (SGLT2) inhibitors have been evaluated in large cardiovascular safety studies in which exploratory or post-hoc analyses shed some light on renal outcomes with these agents. Smaller studies focused on efficacy and safety in patients with T2DM and diabetic kidney disease also provide some evidence of renal outcomes. As a class, both DPP4 inhibitors and GLP1 agonists show promise in reducing albuminuria but have so far not been shown to impact more robust renal outcomes such as doubling of serum creatinine or progression in renal insufficiency. More compelling data exist on the benefits of SGLT2 inhibitors. From the cardiovascular safety studies, empagliflozin, canagliflozin, and dapagliflozin have shown reductions in not just albuminuria, but also show significant reductions in progression of renal insufficiency and a small reduction in the development of end-stage renal disease. The cardiovascular safety studies, however, were not designed to specifically assess renal benefit. Canagliflozin in a landmark trial specifically designed to evaluate its use in patients with diabetes and DKD, has shown to reduce doubling of serum creatinine, progression to end-stage renal disease while also demonstrating a reduction in cardiovascular morbidity as well. It is the first agent in nearly twenty years to obtain an indication for the treatment of DKD.
Keywords:
Published on: May 11, 2020 Pages: 12-17
Full Text PDF
Full Text HTML
DOI: 10.17352/2455-8583.000041
CrossMark
Publons
Harvard Library HOLLIS
Search IT
Semantic Scholar
Get Citation
Base Search
Scilit
OAI-PMH
ResearchGate
Academic Microsoft
GrowKudos
Universite de Paris
UW Libraries
SJSU King Library
SJSU King Library
NUS Library
McGill
DET KGL BIBLiOTEK
JCU Discovery
Universidad De Lima
WorldCat
VU on WorldCat
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."